Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
GLP-1 drugs first helped people manage Type 2 diabetes. Today, doctors also use them widely for weight loss. Researchers are now exploring whether these medications could also affect breast cancer risk and outcomes.
Early studies suggest that GLP-1 drugs may offer potential benefits for breast cancer prevention and treatment. Some findings show lower cancer risk among GLP-1 users. Other research points to better outcomes after a breast cancer diagnosis.
However, researchers still need stronger evidence. Most studies so far have relied on medical records or other retrospective data. These studies can identify trends, but they cannot prove that GLP-1 drugs directly cause better cancer outcomes.
These findings look promising and could guide future research. Scientists want to understand how GLP-1 drugs affect obesity, inflammation, metabolism, and other factors linked to cancer. More research could help explain whether these drugs offer benefits beyond weight loss and diabetes management.
How GLP-1s Function: GLP-1, or glucagon-like peptide-1, is a natural hormone that helps control blood sugar. It also stimulates insulin production and helps people feel full for longer.
GLP-1 medications mimic the effects of this hormone. Common examples include semaglutide, found in Ozempic and Wegovy, and tirzepatide, found in Mounjaro and Zepbound.
Doctors use these medications to manage Type 2 diabetes and obesity. Some GLP-1 medications also help reduce the risk of certain heart-related problems.
Lower Risk of Developing Breast Cancer: Several large studies have linked GLP-1 use with a lower risk of breast cancer. One study followed more than 110,000 women with obesity, ages 45 to 80. It found that GLP-1 users had about a 30% lower breast cancer risk than non-users.
Another study included nearly 230,000 participants. Researchers found that GLP-1 users had a 41% lower risk of obesity-related cancers, including breast cancer, compared with people who relied on diet and exercise alone. Tirzepatide users also showed a greater risk reduction than semaglutide users.
A third study of about 149,000 obese women without diabetes found a slightly lower rate of hormone receptor-positive, HER2-negative breast cancer among GLP-1 users.
However, these findings show an association, not proof that GLP-1 drugs prevent breast cancer. Researchers need more studies to determine whether GLP-1 medications directly reduce cancer risk.
Possibly Slowing Metastasis: A study of more than 10,200 patients with stage I–III lung, breast, colorectal, or liver cancer found a promising association. Patients who started GLP-1 medications after their diagnosis were less likely to develop cancer spread than those who did not use these drugs.
However, the findings show an association, not proof that GLP-1 medications prevent cancer from spreading. More research is needed to understand whether GLP-1 drugs have a direct effect on cancer progression.
Fewer Treatment Side Effects: GLP-1 medications may help lessen some side effects linked to cancer treatment, especially in people with excess weight. Early research suggests these drugs could offer additional benefits during cancer care.
In one study, patients with hormone receptor-positive breast cancer who took CDK4/6 inhibitors without GLP-1 medications experienced adverse effects slightly earlier and more often. The differences were modest, so further research is needed.
Another analysis of more than 5,600 chemotherapy patients found fewer complications among GLP-1 users. They had lower rates of anemia, blood clots, low white blood cell counts, sepsis, nausea, vomiting, fatigue, heart problems, and neuropathy.
A third study looked at nearly 62,000 patients who underwent mastectomy. GLP-1 users had a 63% lower risk of developing lymphedema.
These findings are encouraging, but they do not prove that GLP-1 medications prevent cancer treatment side effects. More research is needed to understand whether the drugs directly cause these benefits.
Better Survival in Invasive Breast Cancer: Several studies link GLP-1 use with better survival in people with breast cancer. One review of nearly 1,600 women found that GLP-1 users had a 60% lower risk of death over 10 years. Another study of nearly 8,800 patients found a 46% lower risk of death over about 5.5 years.
However, these studies have limitations, including missing information about cancer type and treatment history. More research is needed to determine whether GLP-1 medications directly improve breast cancer survival. Among people with diabetes and breast cancer that had spread to the brain, GLP-1 users had a 32% lower three-year risk of death. This benefit was seen with semaglutide, dulaglutide, and tirzepatide, but not liraglutide.
Encouraging Results in DCIS GLP-1 users had a five-year survival rate of 93.5% compared to 85.7% for non-users and a 74% lower risk of their disease developing into invasive or metastatic cancer among over 3,000 patients with hormone receptor-positive DCIS receiving hormonal therapy. However, the exceptionally high rate of metastatic progression in this study raises concerns regarding the precision of the initial DCIS diagnoses, researchers said.
All participants in these studies were taking GLP-1s for diabetes, obesity, or both. No research yet has examined effects in people without those conditions, though new studies are beginning to explore this. Additionally, every study so far has been retrospective, meaning researchers looked backward at existing health records rather than tracking outcomes forward in real time.
Despite these limitations, the findings support a broader idea. Cancer risk and progression may depend on more than genetics. Metabolism, inflammation, and body composition may also play important roles.
